AKTS Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

20.525

Open

20.525

VWAP

20.00

Vol

203.00K

Mkt Cap

1.00B

Low

19.255

Amount

4.00M

EV/EBITDA(TTM)

Total Shares

53.00M

37.00M

EV/OCF(TTM)

P/S(TTM)

0.00

Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.

Events Timeline

(ET)

2026-01-12

11:20:00

Aktis Oncology Shares Surge Over 5% on First Trading Day

2026-01-09 (ET)

2026-01-09

11:20:00

Aktis Oncology Prices IPO at $18 Per Share

2026-01-09

06:20:00

IPO Priced at High End of $16.00-$18.00 Range

2026-01-05 (ET)

2026-01-05

13:30:00

JPMorgan, BofA, and Others Jointly Manage New Stock Offering

News

5.0

01-13NASDAQ.COM

Helen Kim Acquires 835,000 Shares of AKTS for $15.03M Investment

8.5

01-13Globenewswire

Aktis Oncology Closes Upsized IPO Raising $365.4 Million

8.5

01-11renaissancecapital

Aktis Oncology Prices Upsized IPO at $1 Billion Market Cap, Closes +24%

8.5

01-10renaissancecapital

Aktis Oncology Prices Upsized IPO at $318 Million, Targets Solid Tumors

8.5

01-09Newsfilter

Vida Ventures Supports Aktis IPO, Raising $318 Million

8.5

01-09renaissancecapital

Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly

Valuation Metrics

The current forward P/E ratio for Aktis Oncology Inc (AKTS.O) is -0.02, compared to its 5-year average forward P/E of -5.75. For a more detailed relative valuation and DCF analysis to assess Aktis Oncology Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.75

Current PE

-0.02

Overvalued PE

-0.25

Undervalued PE

-11.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.96

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.44

Undervalued EV/EBITDA

-10.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.90

Current PS

0.02

Overvalued PS

20.58

Undervalued PS

-0.78

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

which stock will moon this year?

Intellectia · 722 candidates

Market Cap: >= 1.00MQuarter Revenue Yoy Growth: >= 0.0%Revenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEYtd Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

TGTX

TG Therapeutics Inc

5.00B

MARA

MARA Holdings Inc

4.00B

IREN

IREN Ltd

17.00B

LCID

Lucid Group Inc

4.00B

SMR

Nuscale Power Corp

6.00B

CLSK

CleanSpark Inc

3.00B

Whales Holding AKTS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Aktis Oncology Inc (AKTS) stock price today?

The current price of AKTS is 19.71 USD — it has decreased -3.85 % in the last trading day.

What is Aktis Oncology Inc (AKTS)'s business?

What is the price predicton of AKTS Stock?

Wall Street analysts forecast AKTS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Aktis Oncology Inc (AKTS)'s revenue for the last quarter?

Aktis Oncology Inc revenue for the last quarter amounts to 9.00M USD, increased 28.92 % YoY.

What is Aktis Oncology Inc (AKTS)'s earnings per share (EPS) for the last quarter?

Aktis Oncology Inc. EPS for the last quarter amounts to -0.04 USD, decreased -85.71 % YoY.

How many employees does Aktis Oncology Inc (AKTS). have?

Aktis Oncology Inc (AKTS) has 117 emplpoyees as of January 29 2026.

What is Aktis Oncology Inc (AKTS) market cap?

Today AKTS has the market capitalization of 1.00B USD.

AKTS Overview